Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer

NCT01642771 is registered in ClinicalTrials.gov with China Breast Cancer Clinical Study Group as lead sponsor.

NCT NCT01642771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01642771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
Lead sponsor
China Breast Cancer Clinical Study Group
Phase
Phase 3
Overall status
Unknown status
Start date
June 30, 2012
Completion date
May 31, 2020
Enrollment
636 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer